We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CIBEST:BVCGrupo Cibest S.A. Analysis

Data as of 2026-03-16 - not real-time

COP 80,980.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Grupo Cibest trades at COP 80,980, sitting just below its 20‑day SMA (COP 84,096) and 50‑day SMA (COP 81,882) but comfortably above the 200‑day SMA (COP 64,503), indicating a short‑term pullback within a longer‑term bullish framework. The RSI of 47 signals a neutral momentum, while the MACD is in a bearish configuration, suggesting that downside pressure could test the near‑term support at COP 74,940 before any upside toward the resistance level of COP 99,000. Volatility remains high at roughly 64% over the past 30 days, yet the stock’s beta of 0.21 points to limited systematic risk, a factor reinforced by the “Greed” sentiment reading of 72.9 on the Fear‑Greed Index. Fundamentals are solid: a PE of 11.3 versus the industry average of 16.4, a robust ROE of 16%, operating margin of 37.5%, and a dividend yield of 5.57% with a payout ratio near 55% indicate a healthy, cash‑generating business. Recent earnings calls highlighted a net income of COP 3.8 trillion for FY 2025 (COP 7.3 trillion excluding the Banistmo impairment), underscoring earnings resilience despite modest revenue growth.
Valuation appears stretched relative to analyst targets (median price COP 62,600) but remains attractive on a value basis given the low PE, high dividend, and solid return metrics. The dividend appears sustainable, supported by ample cash balances and low leverage, positioning the stock as a compelling income play while the upside potential is limited in the near term, making a cautious hold stance appropriate pending price correction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price approaching technical support at COP 74,940
  • Bearish MACD histogram indicating near‑term downside
  • High dividend yield providing downside buffer

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong ROE and operating margins supporting earnings stability
  • Valuation gap with industry peers (low PE, attractive dividend)
  • Analyst consensus of hold with median target below current price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustainable dividend and low payout ratio
  • Low beta and solid balance sheet indicating resilience
  • Potential price correction aligning market price with intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth-0.20%
Profit Margin16.18%
P/E Ratio11.3
ROE16.24%
ROA1.85%
P/B Ratio1.9
Industry P/E16.4

Technical Analysis

TrendBullish
RSI47.3
SupportCOP 74,940.00
ResistanceCOP 99,000.00
MA 20COP 84,096.00
MA 50COP 81,881.60
MA 200COP 64,502.70
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Target PriceCOP 60,763.13
Upside/Downside-24.97%
GradeFair
TypeValue
Dividend Yield5.57%

Risk Assessment

Beta0.21
Volatility63.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.